Nurry Hong

Nurry is a passionate patient advocate for all those suffering with severe food allergies. As a father of a son with multiple food allergies, Nurry has focused his professional efforts to advance innovations to solve the needs of patients suffering from severe allergies. As part of the Bryn team, Nurry is compelled to create A Better Way for people at risk for anaphylaxis.

Nurry has over 20 years of experience in life sciences and healthcare. His experience spans multiple senior executive and advisory roles working for publicly traded biopharma, private biotech, seed-stage ventures, investment funds and non-profit research organizations. He is an accomplished industry executive, biotech entrepreneur, and a recognized leader in food allergies. He is a business leader with strengths in strategy, business development, finance, patient-driven product development and commercialization, and market access. Nurry has a breadth of experience across a range of therapeutic areas, including in-depth expertise in immunology, pathways for disease tolerance, the human microbiome, and pediatric health.

Prior to joining Bryn, Nurry led the creation of Pareto Bio, a Harvard-affiliated preclinical stage biotech company focused on harnessing the microbiome to affect regulatory mechanisms to induce disease tolerance. Nurry was also previously Chief of Strategy and Innovation of FARE, the leading advocacy group for people suffering from food allergies, and Managing Director and Partner of L.E.K. Consulting, one of the world’s leading corporate strategy and life sciences consultancies.